Developer docs
API playgroundTry for free, no card

Search company profiles

Jarvik Heart

Full company profile

uuid000b7ta

Namestring
Jarvik Heart
Websiteurl
jarvikheart.com
Company typeenum
Private
Founded yearint
1988
Descriptiontext

Jarvik Heart is a privately held medical device company headquartered in New York and founded in 1988 by Robert Jarvik, a pioneering figure in artificial heart development. The firm specializes in mechanical circulatory support devices, with its primary product being the Jarvik 2200 artificial heart, introduced in 2023–2024 as part of the broader artificial organ and bionics market. The device targets patients with end-stage or severe heart failure who require mechanical circulatory support either as a bridge to transplant or as destination therapy when donor hearts are unavailable.

The company's underlying technology rests on ventricular assist device and total artificial heart engineering, with the Jarvik 2200 characterized in available sources as a novel-method-architecture design. Jarvik Heart operates with a small team of 51–100 employees, consistent with a clinical-stage or early-commercial medical device firm executing R&D, regulatory engagement, and limited manufacturing. Pricing is not publicly disclosed; medical devices of this class are typically monetized through hospital procurement channels and insurance reimbursement rather than direct patient sales.

Jarvik Heart's business model is anchored in regulated medical device commercialization: developing Class III implantable cardiac hardware, navigating FDA premarket pathways, and selling through specialty cardiac surgery centers and transplant programs. The company has limited publicly disclosed fundraising activity — a 2019 BIRD Foundation engagement is the only funding event on record, with $0 raised — and no customer logos, geographic markets, or distribution channel details are disclosed. Leadership comprises founder-CEO Robert Jarvik and COO Peter Hinchliffe, with no broader management team surfaced in the source material.

Short descriptiontext

Jarvik Heart is a privately held New York-based medical device company, founded in 1988, that develops the Jarvik 2200 artificial heart and related mechanical circulatory support devices for patients with severe or end-stage heart failure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ventricular assist devices, artificial heart technology, mechanical circulatory support, heart failure treatment, cardiac assist devices
Industry3 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAD
Heart Failure & Transplant Cardiology
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Mechanical Circulatory Support Devices
Social media profiles1 record
Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Jarvik Heart develops and manufactures miniaturized mechanical circulatory support devices, principally the Jarvik 2200 artificial heart, for patients with end-stage heart failure who require long-term mechanical support as a bridge to transplant or destination therapy. The company sells implantable cardiac hardware to hospitals, cardiac surgery centers, and transplant programs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Jarvik Heart offers medical devices focused on mechanical circulatory support. The company's primary product is the Jarvik 2200 artificial heart, which provides long-term mechanical support for patients with severe heart failure.

Product and service1 record
1Jarvik 2200 artificial heart
CategoryMechanical Circulatory Support Devices
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Terumo has cardiovascular and ventricular assist device programs through its Terumo Cardiovascular division. It is a broad incumbent whose mechanical circulatory support efforts and capital resources make it both a competitive threat and a potential strategic partner for Jarvik Heart.

TypeBroad incumbent
Description

Medtronic acquired HeartWare International, giving it a mechanical circulatory support platform. As a broad incumbent in cardiac and vascular devices, Medtronic competes for the same end-stage heart failure market and represents potential strategic interest for Jarvik Heart's technology.

TypeDirect peer
Description

SynCardia is the most directly comparable peer, developing the SynCardia Total Artificial Heart for end-stage biventricular heart failure. Both companies target the same patient population with similar mechanical circulatory support concepts, though SynCardia has established FDA status and a longer commercial history.

4ReliantHeart
TypeEmerging player
Description

ReliantHeart developed the HeartAssist5 (aVAD) ventricular assist device targeting advanced heart failure. As a smaller company focused on mechanical circulatory support, it is comparable to Jarvik Heart in scale and category focus.

TypeEmerging player
Description

BiVACOR is developing a total artificial heart using rotary blood pump technology, targeting the same end-stage heart failure population as Jarvik Heart. It represents an emerging competitor with significant government and venture backing, illustrating the capital scale required to compete in this category.

6Carmat
TypeEmerging player
Description

Carmat is developing a bioprosthetic total artificial heart targeting end-stage biventricular heart failure, making it a direct technological comparator to the Jarvik 2200. As a European-listed company, it provides a public-market reference point for total artificial heart development timelines and capital requirements.

7Abbott
TypeBroad incumbent
Description

Abbott is the dominant player in mechanical circulatory support through the HeartMate 3 LVAD franchise and broader cardiovascular device portfolio. While its primary focus is LVADs rather than total artificial hearts, it sets the standard of care against which Jarvik Heart must compete and represents the most likely strategic acquirer.

TypeBroad incumbent
Description

LivaNova is a cardiovascular device company with heart failure and mechanical circulatory support exposure. While it has divested some heart valve lines, its broader cardiovascular portfolio and capital base position it as a comparable broad incumbent in the same disease category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jarvik Heart

Mechanical Circulatory Support Devicesjarvikheart.com

Jarvik Heart is a privately held New York-based medical device company, founded in 1988, that develops the Jarvik 2200 artificial heart and related mechanical circulatory support devices for patients with severe or end-stage heart failure.

What Jarvik Heart does

Jarvik Heart is a privately held medical device company headquartered in New York and founded in 1988 by Robert Jarvik, a pioneering figure in artificial heart development. The firm specializes in mechanical circulatory support devices, with its primary product being the Jarvik 2200 artificial heart, introduced in 2023–2024 as part of the broader artificial organ and bionics market. The device targets patients with end-stage or severe heart failure who require mechanical circulatory support either as a bridge to transplant or as destination therapy when donor hearts are unavailable.

The company's underlying technology rests on ventricular assist device and total artificial heart engineering, with the Jarvik 2200 characterized in available sources as a novel-method-architecture design. Jarvik Heart operates with a small team of 51–100 employees, consistent with a clinical-stage or early-commercial medical device firm executing R&D, regulatory engagement, and limited manufacturing. Pricing is not publicly disclosed; medical devices of this class are typically monetized through hospital procurement channels and insurance reimbursement rather than direct patient sales.

Jarvik Heart's business model is anchored in regulated medical device commercialization: developing Class III implantable cardiac hardware, navigating FDA premarket pathways, and selling through specialty cardiac surgery centers and transplant programs. The company has limited publicly disclosed fundraising activity — a 2019 BIRD Foundation engagement is the only funding event on record, with $0 raised — and no customer logos, geographic markets, or distribution channel details are disclosed. Leadership comprises founder-CEO Robert Jarvik and COO Peter Hinchliffe, with no broader management team surfaced in the source material.

Jarvik Heart firmographics

Firmographics
Name
Jarvik Heart
Website
https://jarvikheart.com
Company type
Private
Founded year
1988
Operating status
Operating
Headcount range
11–50 employees
Short description
Jarvik Heart is a privately held New York-based medical device company, founded in 1988, that develops the Jarvik 2200 artificial heart and related mechanical circulatory support devices for patients with severe or end-stage heart failure.
Ownership category
akta.pro rank

Jarvik Heart industry classification

Industry
Product category
Mechanical Circulatory Support Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAD
Heart Failure & Transplant Cardiology

Keywords

  • Ventricular assist devices
  • Artificial heart technology
  • Mechanical circulatory support
  • Heart failure treatment
  • Cardiac assist devices

Where Jarvik Heart is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Jarvik Heart business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure

Jarvik Heart product offering

Product offering

Core offering

Jarvik Heart develops and manufactures miniaturized mechanical circulatory support devices, principally the Jarvik 2200 artificial heart, for patients with end-stage heart failure who require long-term mechanical support as a bridge to transplant or destination therapy. The company sells implantable cardiac hardware to hospitals, cardiac surgery centers, and transplant programs.

Product overview

Jarvik Heart offers medical devices focused on mechanical circulatory support. The company's primary product is the Jarvik 2200 artificial heart, which provides long-term mechanical support for patients with severe heart failure.

Differentiator

Problem solved

Functional benefit

Products and services

  • Jarvik 2200 artificial heart

Companies that use Jarvik Heart

Customer profile

Ideal customer profiles1 record

Jarvik Heart technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Jarvik Heart partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights2 records

Jarvik Heart competitors and assessment

Company assessment

Broad incumbents

  • Terumo: Terumo has cardiovascular and ventricular assist device programs through its Terumo Cardiovascular division. It is a broad incumbent whose mechanical circulatory support efforts and capital resources make it both a competitive threat and a potential strategic partner for Jarvik Heart.
  • Medtronic: Medtronic acquired HeartWare International, giving it a mechanical circulatory support platform. As a broad incumbent in cardiac and vascular devices, Medtronic competes for the same end-stage heart failure market and represents potential strategic interest for Jarvik Heart's technology.
  • Abbott: Abbott is the dominant player in mechanical circulatory support through the HeartMate 3 LVAD franchise and broader cardiovascular device portfolio. While its primary focus is LVADs rather than total artificial hearts, it sets the standard of care against which Jarvik Heart must compete and represents the most likely strategic acquirer.
  • LivaNova: LivaNova is a cardiovascular device company with heart failure and mechanical circulatory support exposure. While it has divested some heart valve lines, its broader cardiovascular portfolio and capital base position it as a comparable broad incumbent in the same disease category.

Direct peers

  • SynCardia Systems: SynCardia is the most directly comparable peer, developing the SynCardia Total Artificial Heart for end-stage biventricular heart failure. Both companies target the same patient population with similar mechanical circulatory support concepts, though SynCardia has established FDA status and a longer commercial history.

Emerging players

  • ReliantHeart: ReliantHeart developed the HeartAssist5 (aVAD) ventricular assist device targeting advanced heart failure. As a smaller company focused on mechanical circulatory support, it is comparable to Jarvik Heart in scale and category focus.
  • BiVACOR: BiVACOR is developing a total artificial heart using rotary blood pump technology, targeting the same end-stage heart failure population as Jarvik Heart. It represents an emerging competitor with significant government and venture backing, illustrating the capital scale required to compete in this category.
  • Carmat: Carmat is developing a bioprosthetic total artificial heart targeting end-stage biventricular heart failure, making it a direct technological comparator to the Jarvik 2200. As a European-listed company, it provides a public-market reference point for total artificial heart development timelines and capital requirements.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Jarvik Heart social profiles

Digital presence

Jarvik Heart financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jarvik Heart leadership team

Management profile

Number of profiles

Profiles2 records

Jarvik Heart funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jarvik Heart M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jarvik Heart

What does Jarvik Heart do?

Jarvik Heart develops and manufactures miniaturized mechanical circulatory support devices, principally the Jarvik 2200 artificial heart, for patients with end-stage heart failure who require long-term mechanical support as a bridge to transplant or destination therapy. The company sells implantable cardiac hardware to hospitals, cardiac surgery centers, and transplant programs.

When was Jarvik Heart founded?

Jarvik Heart was founded in 1988. It employs 11 to 50 people.

Where is Jarvik Heart based?

Jarvik Heart is headquartered in New York, United States, in the North America region.

Who are Jarvik Heart's main competitors?

Broad incumbents on record are Terumo, Medtronic, Abbott and LivaNova. SynCardia Systems is listed as a direct peer. Emerging players are ReliantHeart, BiVACOR and Carmat.

Does Jarvik Heart have an API?

No public API is recorded for Jarvik Heart.

What industry is Jarvik Heart in?

Jarvik Heart's product category is Mechanical Circulatory Support Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Global Market Insights Inc.Ventricular Assist Devices Market Size & Share Report, 2034The global ventricular assist devices market was valued at USD 2.5 billion in 2024 and is projected to grow to USD 5.7 billion by 2034, driven by the increasing prevalence of heart failures and cardiovascular diseases. Major players include Abbott, Johnson & Johnson, Berlin Heart, and Jarvik HEART, who collectively held a market share of approximately 93% in 2024. The demand for these devices is significantly influenced by technological advancements and the need for better treatment options due to shortages of heart donors.PR NewswireLeviticus Cardio & Jarvik Heart Unveil Groundbreaking Wireless Heart Pump SystemLeviticus Cardio and Jarvik Heart announced the successful first human implantation of FIVAD (Fully Implanted Ventricular Assist Device), a wireless heart pump system, at the National Research Center for Cardiac Surgery in Astana, Kazakhstan in December 2018, with the patient discharged and resuming normal life. The FIVAD system uses patented Coplanar Energy Transfer technology to wirelessly power a Jarvik 2000 pump, freeing patients from external wires for up to 8 hours daily and reducing infection risks associated with traditional drivelines. Both companies CEOs jointly stated the technology represents a game-changing advancement for severe heart failure patients, with plans to expand the procedure to additional patients.PR NewswireLeviticus Cardio and Jarvik Heart Awarded R&D Grant From the Prestigious BIRD FoundationLeviticus Cardio and Jarvik Heart have been awarded a $950,000 grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation to fund development of a fully implanted wireless ventricular assist device (VAD) system. The funding will support the first phase of the $2.9 million project, which is designed to advance toward clinical regulatory trials for the hybrid system combining Jarvik Heart's pump with Leviticus' coplanar energy transfer technology. The grant follows successful long-term animal trials spanning six months.PR NewswireGlobal Artificial Organs Industry - Annual estimates and forecasts 2015 - 2022Reportlinker published a comprehensive market research report analyzing the worldwide artificial organs industry, covering product segments including artificial hearts, kidneys, liver, pancreas, and lungs, with annual estimates and forecasts from 2015 through 2022. The report provides market data and analytics for the US and Rest of World markets, profiling 48 companies operating in this medical technology sector. Key growth drivers identified include the aging global population, rising prevalence of diabetes and kidney disease, technological advancements, and ongoing organ donor shortages.PR NewswireResearch and Markets - Global LVAD Market 2016-2020 with Abiomed, Berlin Heart, HeartWare International, Jarvik Heart & St. Jude Medical DominatingResearch and Markets announced the release of its 'Global LVAD Market 2016-2020' report, projecting the market to grow at a CAGR of 13.19% over the forecast period. The report identifies key growth drivers including a shortage of heart donors, with the average waiting time for heart transplantation in the US reaching 9-11 months and up to two years in most cases, while noting challenges from alternative treatments such as heart transplantation and drug therapy. Notable M&A activity discussed includes St. Jude Medical's acquisition of Thoratec for approximately $3.3 billion in October 2015 and HeartWare International's acquisition of Valtech Cardio, reflecting a broader trend of consolidation in the LVAD market.